HEALIUS LIMITED (HLS)

Latest AI Signal: SELL
Status: AGING
Days Old: 7

Confidence: 75.00%

Date: 14-05-2026

Price: $0.375

Last Price: $0.345

Post-Signal Low Price: $0.345

Latest  HEALIUS LIMITED(HLS)   News

03 May 2026, 04:27 PM

Australia pledges A$1.8 billion for Medicare clinics amid widening deficit fears

Investing.com -- Australian Prime Minister Anthony Albanese announced on Sunday that the upcoming federal budget will include a significant funding boost for Medicare urgent care clinics, according to a report from Bloomberg. The government plans to allocate an additional A$1.8 billion ($1.3 billio

15 Dec 2023, 11:52 AM

Australian Clinical Labs Withdraws Takeover Offer for Healius

Australian Clinical Labs withdrew its takeover offer for Healius, citing the deteriorating performance of its pathology services rival rather than opposition from Australia’s competition regulator. Continue reading

31 Aug 2023, 09:15 PM

Health Care Roundup: Market Talk

The Australian healthcare company’s base pathology business delivered revenue growth of 4% in 2H and management believes it has addressed the division’s cost base. “Volume growth will be a key focus for FY 2024 to drive margin,” analyst David Stanton says in a note. “In terms of pathology Ebit margi

02 Nov 2022, 11:00 PM

RingCentral Selected by Healius to Transform Telephony and Contact Center Platform Australia-wide

Communications enhancements to improve the doctor and patient experience SYDNEY, Australia & BELMONT, Calif., November 02, 2022--(BUSINESS WIRE)--Healius Limited (Healius) (ASX: HLS), one of Australia’s leading healthcare companies, has selected RingCentral, Inc. (NYSE: RNG) to deploy an integrated

30 Aug 2022, 11:00 PM

C2N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia

ST. LOUIS, August 30, 2022--(BUSINESS WIRE)--C2N Diagnostics, a leader in advanced brain health diagnostics, and Healius Ltd (ASX:HLS), one of Australia's leading listed healthcare companies, today announced a partnership that will aim to bring C2N’s PrecivityAD™ blood test and related brain health

Chart available once enough post-signal price data is available.

Sell Confidence High

AI Confidence - 75.00 % model confidence

Business Overview

Healius Limited is an Australian healthcare company providing diagnostic imaging, pathology, and day hospital services. It holds a strong market position in the Australian healthcare sector with a broad network of diagnostic centers and hospitals, catering to both public and private patients.

Financial Analysis

Cash Flow	Moderate
Debt	Moderate
Profitability	Moderate
Revenue Trend	Flat

Technical Analysis

Trend	Bearish
Momentum	Weak
RSI Signal	Oversold
Support Level	$ 0.36
Resistance Level	$ 0.40

Valuation

Valuation - Fairly Valued

The stock trades near historical average multiples reflecting current earnings and growth expectations, with limited upside given sector challenges.

Catalysts

• Potential margin improvement from operational efficiencies

• Strategic partnerships or acquisitions to expand service offerings

Recommendation

Action - Sell

Timeframe - Medium Term

Given the flat revenue outlook, moderate profitability, and bearish technical signals, combined with regulatory and competitive risks, the stock is expected to underperform in the medium term. Investors should consider reducing exposure.